Eric M. Reiman, MD

Chief Executive Officer, Banner Research
Executive Director, Banner Alzheimer’s Institute

Dr. Eric Reiman is Chief Executive Officer of Banner Research and Executive Director at Banner Alzheimer’s Institute (BAI). He is also Director of the Arizona Alzheimer’s Consortium, Clinical Director of Neurogenomics at the Translational Genomics Research Institute (TGen), Professor of Psychiatry at the University of Arizona and University Professor of Neuroscience at Arizona State University.

Dr. Reiman and his Banner Alzheimer’s Institute colleagues established the Alzheimer’s Prevention Initiative to launch a new era in Alzheimer’s prevention research. The Alzheimer’s Prevention Initiative includes public-private partnerships, prevention trials and biomarker development programs in cognitively unimpaired persons at high genetic and/or biomarker risk for Alzheimer’s disease. Unusually large registries and innovative programs to support enrollment in these and other studies, precedent-setting trial data and biological sample sharing agreements, and other efforts to help find and support the approval, affordability and availability of prevention therapies as soon as possible are also focus areas of this initiative.

Dr. Reiman received his undergraduate and medical education at Duke University and his Psychiatry Residency Training at Duke and Washington Universities. He launched his career in brain imaging research under the mentorship of Marcus Raichle at Washington University in St. Louis and went on to play leadership roles in brain imaging, brain mapping, genomics research, the unusually early detection and tracking of Alzheimer’s disease and the accelerated evaluation of Alzheimer’s prevention therapies. He has also sought to advance new models of biomedical research collaboration and dementia care.

Dr. Reiman is an author of more than 400 publications, a principal investigator of six current grants awarded by the National Institutes of Health and a member of the National Advisory Council on Aging, which advises the directors of both the National Institutes of Health and the National Institute on Aging as well as the Secretary of the U.S. Department of Health and Human Services. He is a recipient of the Potamkin Prize for his pioneering contributions to the study of preclinical Alzheimer’s disease and the accelerated evaluation of Alzheimer’s prevention therapies.